GSK plc (NYSE:GSK) Shares Sold by Trust Co. of Toledo NA OH

Trust Co. of Toledo NA OH lowered its holdings in shares of GSK plc (NYSE:GSK) by 14.7% in the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 27,873 shares of the pharmaceutical company’s stock after selling 4,806 shares during the period. Trust Co. of Toledo NA OH’s holdings in GSK were worth $943,000 as of its most recent SEC filing.

A number of other large investors have also recently bought and sold shares of the business. Sunbelt Securities Inc. lifted its stake in shares of GSK by 73.8% in the 3rd quarter. Sunbelt Securities Inc. now owns 711 shares of the pharmaceutical company’s stock worth $29,000 after acquiring an additional 302 shares during the period. EverSource Wealth Advisors LLC lifted its stake in shares of GSK by 9.4% in the 2nd quarter. EverSource Wealth Advisors LLC now owns 3,542 shares of the pharmaceutical company’s stock worth $137,000 after acquiring an additional 303 shares during the period. Mesirow Financial Investment Management Inc. lifted its stake in shares of GSK by 2.0% in the 3rd quarter. Mesirow Financial Investment Management Inc. now owns 16,693 shares of the pharmaceutical company’s stock worth $682,000 after acquiring an additional 323 shares during the period. Rehmann Capital Advisory Group lifted its stake in shares of GSK by 6.3% in the 3rd quarter. Rehmann Capital Advisory Group now owns 5,608 shares of the pharmaceutical company’s stock worth $232,000 after acquiring an additional 332 shares during the period. Finally, Investment Partners Asset Management Inc. lifted its stake in shares of GSK by 2.3% in the 3rd quarter. Investment Partners Asset Management Inc. now owns 15,559 shares of the pharmaceutical company’s stock worth $636,000 after acquiring an additional 344 shares during the period. Institutional investors and hedge funds own 15.74% of the company’s stock.

Analyst Ratings Changes

GSK has been the subject of several recent analyst reports. Deutsche Bank Aktiengesellschaft cut shares of GSK from a “buy” rating to a “hold” rating in a research note on Friday, November 15th. Jefferies Financial Group cut shares of GSK from a “buy” rating to a “hold” rating and reduced their price objective for the company from $53.00 to $39.50 in a research note on Tuesday, November 12th. Guggenheim cut shares of GSK from a “buy” rating to a “neutral” rating in a research note on Thursday, October 31st. Finally, StockNews.com upgraded shares of GSK from a “buy” rating to a “strong-buy” rating in a research note on Monday. Seven equities research analysts have rated the stock with a hold rating and four have assigned a strong buy rating to the stock. Based on data from MarketBeat.com, GSK currently has an average rating of “Moderate Buy” and a consensus price target of $43.25.

GSK Stock Performance

NYSE:GSK opened at $32.71 on Tuesday. The company has a current ratio of 0.81, a quick ratio of 0.53 and a debt-to-equity ratio of 0.98. The firm has a 50-day moving average price of $34.30 and a two-hundred day moving average price of $38.12. GSK plc has a twelve month low of $32.55 and a twelve month high of $45.92. The company has a market capitalization of $67.79 billion, a P/E ratio of 21.24, a price-to-earnings-growth ratio of 1.52 and a beta of 0.63.

GSK Increases Dividend

The company also recently declared a quarterly dividend, which was paid on Thursday, January 9th. Stockholders of record on Friday, November 15th were issued a dividend of $0.3928 per share. The ex-dividend date was Friday, November 15th. This is an increase from GSK’s previous quarterly dividend of $0.38. This represents a $1.57 dividend on an annualized basis and a dividend yield of 4.80%. GSK’s payout ratio is 95.45%.

GSK Profile

GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, and specialty and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through two segments, Commercial Operations and Total R&D.